Skip to main content

Table 2 Demographic and medical characteristics of participants

From: The effect of exercise-based interventions on health-related quality of life and physical function in older patients with cancer receiving medical antineoplastic treatments: a systematic review

Author, year

No. of participants

Age

Mean (SD)

Sex

Female/male

Diagnosis

Treatment setting and regimens

Performance status

Comorbidities

Arrieta et al [30], 2019

Total: 301 (300 analyzed)

IG: 150

CG: 150

IG: 76.8 (5.1)

CG: 76.6 (5.0)

180/120

60%/40%

Various cancers (colon, rectum, breast, esophagus, oral, kidney, prostate, bladder, lung, stomach, biliary ducts, ovary, hepato-cellular carcinoma, lymphoma, womb, endometrium, and pancreas)

Cancer stage: NR

Curative treatments

Systemic treatments: chemotherapy (60%), endocrine therapy (20%), targeted therapy (2%)

By ECOG

PS 0: 53%

PS 1: 30%

PS 2: 4%

NR: 13%

By CIRS-G:

No grade 3–4 comorbidities: 79%

1 grade 3–4 comorbidity: 17%

≥2 grade 3–4 comorbidities: 4%

Maréchal et al [31], 2019

Total: 14

IG: 6

CG: 8

IG: 67.7 (2.1)

CG: 69.6 (4.1)

11/3

79%/21%

Breast and colon cancer

Cancer stage: NR

Systemic oncological treatment that started ≤12 weeks (treatment setting not further reported)

NR

NR

Sajid et al [32], 2016

Total: 19

EXCAP: 6

Wii: 8

CG: 5

EXCAP: 75.7 (9.5)

Wii: 77.5 (6.7)

CG: 71.8 (5.0)

0/19

0%/100%

Prostate cancer

Cancer stage: NR

Treatment with ADT for ≥3 months

Treatment setting: stable diseasea

By Karnofsky, mean (SD):

EXCAP: 88.3 (13.3)

Wii: 87.5 (8.9)

CG: 88 (16.4)

No. of comorbidities:

EXCAP; 0–1: 67%, 2: 33%

Wii; 0–1: 75%, 2: 25%

CG; 0–1: 60%, 2: 40%

Miki et al [33], 2014

Total: 78

IG: 38

CG: 40

IG: 73.0 (4.6)

CG: 75.5 (6.6)

43/35

55%/45%

Breast and prostate cancer

Cancer stage:

IG:

Stage I: 28.9%

Stage II: 57.9%

Stage III: 2.6%

Stage IV: 10.5%

CG:

Stage I: 32.5%

Stage II: 37.5%

Stage III: 12.5%

Stage IV: 17.5%

Curative and palliative treatments

Systemic treatment: endocrine therapy (53%), chemotherapy (6%)

NR

NR

  1. Abbreviations: ADT Androgen deprivation therapy, CG Control group, CIRS-G Cumulative Illness Rating Scale-Geriatric, ECOG Eastern Cooperative Oncology Group, IG Intervention group, No. Number, NR Not reported, PS Performance status, PSA Prostate specific antigen, SD Standard deviation
  2. aStable or declining PSA, no progressive clinical symptoms, and no new metastatic lesions for one month prior to inclusion